FDA Approval: Ibrutinib for Patients with Previously Treated Mantle Cell Lymphoma and Previously Treated Chronic Lymphocytic Leukemia

R. Angelo de Claro(Center for Drug Evaluation and Research), Karen M. McGinn(Center for Drug Evaluation and Research), Nicole Verdun(Center for Drug Evaluation and Research), Shwu‐Luan Lee(Center for Drug Evaluation and Research), Haw-Jyh Chiu(Center for Drug Evaluation and Research), Haleh Saber(Center for Drug Evaluation and Research), Margaret E. Brower(Center for Drug Evaluation and Research), Chai‐Ni Chang(Center for Drug Evaluation and Research), Elimika Pfuma(Center for Drug Evaluation and Research), Bahru Habtemariam(Center for Drug Evaluation and Research), Julie Bullock(Center for Drug Evaluation and Research), Yun Wang(Center for Drug Evaluation and Research), Lei Nie(Center for Drug Evaluation and Research), Xiao-Hong Chen(Center for Drug Evaluation and Research), Donghao Lu(Center for Drug Evaluation and Research), Ali Al‐Hakim(Center for Drug Evaluation and Research), Robert C. Kane(Center for Drug Evaluation and Research), Edvardas Kaminskas(Center for Drug Evaluation and Research), Robert Justice(Center for Drug Evaluation and Research), Ann T. Farrell(Center for Drug Evaluation and Research), Richard Pazdur(Center for Drug Evaluation and Research)
Clinical Cancer Research
August 13, 2015
Cited by 163

Abstract

On November 13, 2013, the FDA granted accelerated approval to ibrutinib (IMBRUVICA capsules; Pharmacyclics, Inc.) for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. On February 12, 2014, the FDA granted accelerated approval for the treatment of patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy. Ibrutinib is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor that received all four expedited programs of the FDA: Fast-Track designation, Breakthrough Therapy designation, Priority Review, and Accelerated Approval. Both approvals were based on overall response rate (ORR) and duration of response (DOR) in single-arm clinical trials in patients with prior treatment. In MCL (N = 111), the complete and partial response rates were 17.1% and 48.6%, respectively, for an ORR of 65.8% [95% confidence interval (CI), 56.2%-74.5%]. The median DOR was 17.5 months (95% CI, 15.8-not reached). In CLL (N = 48), the ORR was 58.3% (95% CI, 43.2%-72.4%), and the DOR ranged from 5.6 to 24.2 months. The most common adverse reactions (≥ 30% in either trial) were thrombocytopenia, diarrhea, neutropenia, bruising, upper respiratory tract infection, anemia, fatigue, musculoskeletal pain, peripheral edema, and nausea.


Related Papers

No related papers found

Powered by citation graph analysis